The Cancer Plan for England, introduced in 2000, has promoted cancer service specialisation. We have investigated how far specialisation and general hospital factors each contributed to service performance for four common cancers -breast, colorectal, lung and prostate -at the time of the Cancer Plan.
Introduction.
In the UK National Health Service, patients usually first consult their general practitioner and may then be referred for hospital diagnosis, and treatment if necessary. While cancer is diagnosed in primary care or general hospitals, it is treated in both general hospitals and tertiary care (eg radiotherapy and oncology services). Within a broader process of cancer services development, The Cancer Plan for England 1 in 2000 proposed the development of specialised cancer services for different tumour types, linking general hospitals with tertiary care centres, increasing specialisation in treatment and multi-disciplinary teams. Thirty-four cancer networks were created, confirming geographical and organisational links between hospitals for referral and treatment, and serving populations of between a half and three million. Advice on arrangements for clinical treatment has been set out in the Manual of Cancer Service Standards.
2,3
Within clinical services, specialisation may provide benefits to both doctors and patients.
Specialised clinical teams have greater experience in their use of resources, and in managing variations in clinical condition. In prospective audit studies, specialist cancer services have been shown to achieve better clinical outcomes than generalists. 4,5 Also, association has been shown between clinical outcomes and the volume of patients treated within the specialty. 6, 7 But can hospital-level factors contribute to cancer services performance as well? Studies of cancer outcomes in hospitals have generally used prospectively-gathered clinical data, based on a single operation, disease or specialty. Hospital administrative data may be less detailed than clinical studies, but can be more complete 8, 9 and allow comparison across specialties. In Canada, Urbach and Baxter 10 used administrative data to compare 30-day hospital mortality for five different operations across specialties. They found that mortality for a highlyspecialised operation, pancreatico-duodenectomy, was lower in regional hospitals than in rural low-volume hospitals, but was also lower in regional hospitals with a high volume of lung-resection compared with other high-volume pancreatico-duodenectomy hospitals. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Tables 1 and 2 ) and for each of the six performance measures (Tables 3 and 4 ). The study was approved by the South East
Regional Ethics Committee, England. 
Results
There were relatively few statistically significant associations between the different data sets at cancer network and hospital levels. At cancer network level (Table 1) , 1-yr survival for colorectal cancer (r=0.41, p=0.03) and lung cancer (r=0.43, p=0.03) were positively associated with total standards score -i.e. there was higher short-term survival in networks with higher compliance to standards. There was also a non-significant association for colorectal cancer (r=0.32, p=0.10) for 5-yr survival, but no association for breast cancer at either length of follow-up. Satisfaction, however, showed unexpected trends in the opposite direction: breast cancer 1-yr survival (r=0.34, p=0.47) and lung cancer 5-yr survival (r=0.42, p=0.014) were positively associated with total satisfaction score -i.e. higher short-term survival was associated with greater dissatisfaction. 1-yr relative survival showed no association with in-hospital mortality, while there was a significant inverse association (r=-0.39, p=0.02) for lung cancer 5-yr survival and in-hospital mortality. Waiting times to treatment
were not associated with survival or satisfaction, although for lung cancer (r=0.48, p=0.01)
there was a significant association between waiting times and cancer standards. No associations at all were found for prostate cancer. At hospital trust level (Table 2) , the association between standards and waiting times was significant for breast and colorectal cancers (both r=0.27, p=0.003), but not significant for lung cancer (r=0.17, p=0.07). There were no significant associations between any measures and in-hospital mortality or satisfaction scores.
In contrast, there were strong associations between the different measures for tumour types within the same hospital. At cancer network level ( 
Discussion

Main finding of this study
We have compared rankings of five independent measures of organisational performance for cancer hospitals and networks in the period of the start of the Cancer Plan for England.
Performance measures for hospitals differed more between each other than between the cancer services within them. This suggests that the characteristics of a hospital itself may make an important contribution to cancer services performance.
What is already known on this topic
Evidence indicating that health-care system factors can affect clinical performance over and above individual practice has been reviewed for critical care services, 18 and a literature review of organisational factors in palliative care has been published. 19 The Improving Outcomes
Guidance manuals for specific cancers [20] [21] [22] 
What this study adds
The performance measures did vary to some extent within tumour types. Comparing cancer networks, there was a strong association between 1-yr survival and compliance with standards for colo-rectal and lung cancer, although a lack of association for breast cancer was unexpected. Both breast and lung cancer showed significant associations between (longer) survival and (greater) dissatisfaction. An explanation for these associations through covariance is not clear. In the national survey of cancer patients, 15 dissatisfaction was greater 23 The association between waiting time satisfaction and achievement of cancer service standards for breast and colo-rectal cancers would be expected. The lack of association between higher satisfaction and higher proportion achieving the waiting times standard is less understandable. However, as has been noted, the satisfaction survey was drawn from all patients discharged with a cancer diagnosis, while waiting times data relate to those referred by a GP for treatment: as there are other pathways to a final cancer diagnosis, the two groups of patients would only partly overlap.
The performance measures we used were drawn from a range of sources, and we used only single dimensions. The waiting times for treatment are a sub-set of larger issues of access to services. We looked at cancer standards across specialties, but there are many aspects of hospitals more generally that could be investigated further -for example, in relation to staffing, information flows or research activities. The patient survey recorded responses across various aspects of care, which deserve investigation. Our measure of in-hospital mortality is limited because it depends on hospital discharge policies: hospitals will vary in the extent they are able, or wish, to discharge cancer patients home for terminal care. On the other hand, population-based survival drawn from cancer registries will include a proportion of terminal patients who may not have received in-hospital care.
Limitations of this study
Critical aspects of the study include the observational, cross-sectional design, the use of secondary data, the need for comparisons at aggregate rather than individual level, and multiple statistical testing. Clinical studies based on prospective randomised design provide evidence of the efficacy of a particular treatment; but cannot explore the effects of different settings unless such data are deliberately collected, and observational designs are usually needed for this area of work. 24 The data sets available for the study all related to the period of 2000/1, but a cross-sectional design is less strong than a prospective study. Clinical series can be flawed, because of incomplete data and patient selection, compared with hospital administrative data. [8] [9] Using secondary data also has the advantage of being able to 
Conclusion
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